Administration of inhaled CO reduces leukocytosis, attenuated inflammation and decreases vaso-occlusion in SCD mice (47, 48), while daily oral administration of a saturated liquid formulation of CO enhanced NRF2 and HMOX1 expression and decreased NF-κB activation (49). This evidence concerns the gene HMOX1 and Schnyder corneal dystrophy.